Antileukotriene agents in asthma: The dart that kills the elephant?

CMAJ. Canadian Medical Association Journal

Volumn 160, Issue 2, 1999, Pages 217-223

  Renzi, Paolo M ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CORTICOSTEROID; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; MONTELUKAST; PRANLUKAST; ZAFIRLUKAST; ZILEUTON;

AIRWAY; ASTHMA; BLOOD VESSEL PERMEABILITY; BRONCHOSPASM; HUMAN; INFLAMMATORY CELL; MUCUS; ORAL DRUG ADMINISTRATION; REVIEW; TREATMENT INDICATION;

EID: 0033604892     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. 1. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987;136:225-44.
2. 2. Beasley R, Burgess C, Crane J, Pearce N, Roche W. Pathology of asthma and its clinical implications. J Allergy Clin Immnol 1993;92:148-54.
3. 3. Laitinen LA, Laitinen A, Haahtela T. Airway mucosal inflammation even in patients with newly diagnosed asthma. Am Rev Respir Dis 1993;147:697-704.
4. 4. Ernst P, FitzGerald JM, Spier S. Canadian Asthma Consensus Conference: summary of recommendations. Can Respir J 1996;3:89-100.
5. 5. Djukanovic R, Wilson JW, Britten KM, Wilson SJ, Walls AF, Roche WR, et al. Fffect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992;145:669-74.
6. 6. Cockcroft DW. Practical issues in asthma management: correct use of inhalation devices. Ann Allergy 1993;71:83-4.
7. 7. Toogood JH. Complications of topical steroid therapy for asthma. Am Rev Respir Dis 1990;141(2 pt 2):S89-96.
8. 8. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997;337:8-14.
9. 9. Chen XS, Sheller JR, Johnson EN, Funk CD. Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature 1994;372:179-82.
10. 10. Ford-Hutchinson AW, Gresser M, Young RN. 5-Lipoxygenase. Annu Rev Biochem 1994;63:383-417.
11. 11. Kellaway CH, Trethewie ER. The liberation of a slow-reacting smooth muscle-stimulating substance in anaphylaxis. Q J Exp Physiol Cogn Med Sci 1940;30:121-45.
12. 12. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983;220:568-75.
13. 4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. J Allergy Clin Immunol 1989;84:19-26.
14. 14. Lam S, Chan H, LeRiche JC, Chan-Yeung M, Salari H. Release of leukotrienes in patients with bronchial asthma. J Allergy Clin Immunol 1988;81:711-7.
15. 4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis 1990;142:112-9.
16. 16. Drazen JM, Austen KF. Leukotrienes and airway responses. Am Rev Respir Dis 1987;136:985-98.
17. 17. Hay DW, Torphy TJ, Undem BJ. Cysteinyl leukotrienes in asthma: old mediators up to new tricks. Trends Pharmacol Sci 1995;16:304-9.
18. 4 receptor antagonist, on allergen-induced airway responses in asthmatic subjects [abstract]. Am J Respir Crit Care Med 1996;153:A346.
19. 19. Hamilton AL, Faiferman I, Stober P, Watson PM, O'Byrne PM. Pranlukast (SB205312, ONO 1078), a leukotriene receptor antagonist, attenuates allergen-induced early and late phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects [abstract]. Eur Respir J 1997;10(Suppl 25):419s.
20. 20. Findlay SR, Barden JM, Easley CB, Glass M. Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol 1992;89:1040-5.
21. 21. Hui KP, Taylor IK, Taylor GW, Rubin P, Kesterson J, Barnes NC, et al. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax 1991;46:184-9.
22. 22. Kane GC, Pollice M, Kim CJ, Cohn J, Dworski RT, Murray JJ. A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. J Allergy Clin Immmunol 1996;97:646-54.
23. 23. Fujimura M, Sakamoto S, Kamio Y, Matsuda T. Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthma. Respir Med 1993;87:133-8.
24. 24. Taylor IK, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and, airway hyperreactivity in atopic subjects. Lancet 1991;337:690-4.
25. 25. Fischer AR, McFadden CA, Frantz R, Awni WN, Cohn J, Drazen JM, et al. Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects. Am J Respir Crit Care Med 1995;152:1203-7.
26. 26. Kemp JP, Dockhorn RJ, Shapiro GG, Nguyen HH, Guerrero DA, Reiss TF. Montelukast, leukotriene receptor antagonist, inhibits exercise induced bronchoconstriction in 6-14 year old children [abstract]. J Allergy Clin Immunol 1997;99:S321.
27. 27. Leff JA, Bronsky EA, Kemp J, Pearlman DS, Hendeles L, Busse WW, et al. Montelukast (MK-0476) inhibits exercise-induced bronchoconstriction (EIB) over 12 weeks without causing tolerance [abstract]. Am J Respir Crit Care Med 1997;155:A977.
28. 28. Suguro H, Majima T, Ichimura K, Hashimoto N, Koyama S, Horie T. Effect of a leukotriene antagonist, pranlukast hydrate, on exercise-induced bronchoconstriction [abstract]. Am J Respir Crit Care Med 1997;155:A662.
29. 4 receptor antagonist ICI 204,219 against exercise-induced asthma. Am Rev Respir Dis 1993;147:1413-8.
30. 30. McGill KA, Busse WW. Zileuton. Lancet 1996;348:519-24.
31. 4 (LTD4) antagonist ICI 204, 219 relieves ragweed allergic rhinitis symptoms [abstract]. J Allergy Clin Immunol 1993;91:259.
32. 32. Knapp HR. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N Engl J Med 1990;323:1745-8.
33. 1 receptor antagonist, improves asthma control in aspirin-intolerant asthmatic patients [abstract]. Am J Respir Crit Care Med 1997;155:A977.
34. 34. Yamamoto H, Nagata M, Kuramitsu K, Tabe K, Kiuchi H, Sakamoto Y, et al. Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078. Am J Respir Crit Care Med 1994;150:254-7.
35. 35. Israel E, Fischer AR, Rosenberg MA, Lilly CM, Callery JC, Shapiro J, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993;148:1447-51.
36. 36. Knorr B, Matz J, Bernstein JA, Nguyen H, Seidenberg BC, Reiss TF, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double blind trial. Pediatric Montelukast Study Group. JAMA 1998;279:1181-6.
37. 4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 1996;98:528-34.
38. 38. Kohrogi H, Iwagoe H, Fujii K, Fukuda K, Kawano O, Hamamoto J, et al. The effect of leukotriene antagonist pranlukast on moderate and severe persistent asthma continues more than one year [abstract]. Am J Respir Crit Care Med 1997;155:A662.
39. 4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am J Respir Crit Care Med 1994;150:618-23.
40. 40. Israel E, Rubin P, Kemp JP, Grossman J, Pierson W, Siegel SC, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993;119:1059-66.
41. 41. Leff JA, Pizzichini E, Efthimiadis A, Boulet LP, Wei LX, Weinland DE, et al. Effect of montelukast (MK-0476) on airway eosinophilic inflammation in mildly uncontrolled asthma: a randomized placebo-controlled trial [abstract]. Am J Respir Crit Care Med 1997;155:A977.
42. 42. Ramsay CF, van Kan CI, Nieman RB, Wang J, van Kricken JHJM, Willems LNA, et al. The effects of oral pranlukast on airway immunopathology and clinical parameters in patients with asthma [abstract]. Am J Respir Crit Care Med 1997;155:A502.
43. 43. Munoz NM, Douglas I, Mayer D, Herrnreiter A, Zhu X, Leff AR. Eosinophil chemotaxis inhibited by 5-lipoxygenase blockade and leukotriene receptor antagonism. Am J Respir Crit Care Med 1997;155:1398-1403.
44. 1 receptor antagonist improves the signs and symptoms of asthma over one year of treatment [abstract]. Eur Respir J 1997;10(Suppl 25):437s.
45. 45. Wenzel SE, Chervinsky P, Kerwin E, Silvers W, Faiferman I, Dubb J. Oral pranlukast (Ultair) vs. inhaled beclomethasone: results of a 12-week trial in patients with asthma [abstract]. Am J Respir Crit Care Med 1997;155:A203.
46. 2-agonists [abstract]. Eur Respir J 1997;10(Suppl 25):419s-420s.
47. 47. Leff JA, Israel E, Noonan MJ, Finn AF, Godard P, Lofdahl CG, et al. Montelukast (MK-0476) allows tapering of inhaled corticosteroids (ICS) in asthmatic patients while maintaining clinical stability [abstract]. Am J Respir Crit Care Med 1997;155:A976.
48. 48. Tamaoki J, Kondo M, Sakai N, Nakata J, Takemura H, Nagai A, et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group. Am J Respir Crit Care Med 1997;155:1235-40.
49. 49. Micheletto C, Turco P, Dal Negro R. Accolate 20 mg works as steroid sparing in moderate asthma [abstract]. Am J Respir Crit Care Med 1997;155:A664.
50. 50. Laitinen LA, Zetterstroem O, Holgate ST, Binks SM, Whitney JG. Effects of 'Accolate' (zafirlukast; 20 mg bd) in permitting reduced therapy with inhaled steroids: a multicentre trial in patients with doses of inhaled steroid optimised between 800 and 2000 mcg per day [abstract]. Allergy 1995;50(Suppl 26):320.
51. 51. Sahn SA, Galant S, Murray J, Bronsky E, Spector S, Faiferman I, et al. Pranlukast (Ultair) improves FEV in patients with asthma: results of a 12 week multicenter study vs. nedocromil [abstract]. Am J Respir Crit Care Med 1997;155:A665.
52. 52. Hofstra WB, Sterk PJ, Neijens HJ, van der Weij AM, van Zoest JGCM, Duiverman EJ. Two weeks treatment with zafirlukast (Accolate), sodium cromoglycate or placebo on exercise-induced bronchoconstriction in asthmatic adolescents [abstract]. Am J Respir Crit Care Med 1997;155:A665.
53. 53. Schwartz HJ, Petty T, Reed R, Dubé LM, Swanson LJ. The comparative effects of zileuton, a 5-lipoxygenase inhibitor vs. theophylline in patients with moderate asthma: results from a 13 week, multicenter trial [abstract] Am J Respir Crit Care Med 1995;151:A376.
54. 54. Milgrom H, Bender B, Ackerson L, Bowry P, Smith B, Rand B. Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol 1996;98:1051-7.
55. 55. Boulet LP. Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients. Chest 1998;113:587-92.
56. 56. Zileuton for asthma. Med Lett Drugs Ther 1997;39:18-9.
57. 57. Zafirlukast for asthma. Med Lett Drugs Ther 1996;38:111-2.
58. 58. Wechsler ME, Garpestad E, Flier SR, Kocher O, Weiland DA, Polito AJ, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 1998;279:455-7.
59. 4 receptor antagonist devoid of peroxisomal enzyme induction. Bioorg Med Chem Let 1995;5:283-8.
60. 60. Dworski R, Fitzgerald GA, Oates JA, Sheller JR. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Critic Care Med 1994;149:953-9.